Morgan Boren

Morgan Boren has extensive work experience in the pharmaceutical industry. They started their career at Pfizer Global Research and Development in 1992, where they served as a Toxicology and Histopathology Technician. At Pfizer, they supported lead optimization preclinical development studies and managed the conduct of non-GLP/GLP in-house studies.

In 2005, Morgan joined Amgen Inc as a Senior Associate Scientist, where they managed non-clinical safety evaluation programs for both small and large molecules. They monitored toxicology studies at Contract Research Organizations to ensure adherence to protocols and GLPs, and ensured study timelines were met for regulatory milestones.

Morgan then joined the La Jolla Pharmaceutical Company in 2017 as a Scientist, leading nonclinical toxicology and pharmacokinetic assessments of drug candidates. They evaluated Contract Research Organizations for study conduct and monitored non-GLP and GLP studies.

In 2019, Morgan joined Xeris Pharmaceuticals, Inc. as a Scientist in the Preclinical department. They were responsible for preclinical research and conducted nonclinical studies.

In 2020, Morgan moved to Kinnate Biopharma Inc. as a Principal Investigator in the Nonclinical Development department.

Currently, Morgan is working as an Associate Director at Crinetics Pharmaceuticals, starting in 2024. The details of their role at this company are not specified.

Morgan Boren holds a Master's degree in Biology/Biological Sciences from Brown University. They also earned a BGS degree in Biology from Eastern Connecticut State University. Additionally, they have a Master of Business Administration (M.B.A.) in Business, Management, Marketing, and Related Support Services from Liberty University. Morgan Boren also obtained an Associate of Arts and Sciences - AAS degree in Organic Chemistry from Three Rivers - CT State Community College.